Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: The possible role of metabolic control and oxidative stress
Blood levels of the circulating form of the integrin intercellular adhesion molecule-1 (ICAM-1), malondialdehyde (MDA), and hemoglobin A 1c(HbA 1c) were studied at baseline and 3 months after improved metabolic control in 25 type II diabetic patients without signs of macroangiopathy, and were compar...
Saved in:
Published in | Metabolism, clinical and experimental Vol. 45; no. 4; pp. 498 - 501 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.04.1996
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0026-0495 1532-8600 |
DOI | 10.1016/S0026-0495(96)90226-7 |
Cover
Summary: | Blood levels of the circulating form of the integrin intercellular adhesion molecule-1 (ICAM-1), malondialdehyde (MDA), and hemoglobin A
1c(HbA
1c) were studied at baseline and 3 months after improved metabolic control in 25 type II diabetic patients without signs of macroangiopathy, and were compared with those in 15 matched healthy normal controls. Circulating ICAM-1 and MDA levels were increased in diabetic patients, both at baseline and 3 months later. However, with improving metabolic control HbA
1c, circulating ICAM-1, and MDA significantly decreased. A significant correlation between circulating ICAM-1, HbA
1c, and MDA was found in diabetic patients at each time. Multiple regression analysis considering circulating ICAM-1 as the dependent variable and HbA
1c and MDA as independent variables, showed a significant correlation between the three variables at each time. Similar correlations were found in control subjects. These data show increased levels of circulating ICAM-1 in type II diabetic patients, independent of the presence of macroangiopathy. Moreover, these results suggest that oxidative stress and metabolic control might participate in determining increased circulating ICAM-1 levels in both type II diabetic patients and normal subjects. |
---|---|
Bibliography: | S30 9621917 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0026-0495 1532-8600 |
DOI: | 10.1016/S0026-0495(96)90226-7 |